Tracy J Ruckwardt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2398076/publications.pdf

Version: 2024-02-01

19 papers	3,132 citations	623574 14 h-index	794469 19 g-index
22 all docs	22 docs citations	22 times ranked	6276 citing authors

#	Article	IF	Citations
1	Recurrent respiratory syncytial virus infection in a CD14 deficient patient. Journal of Infectious Diseases, 2022, , .	1.9	5
2	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. PLoS ONE, 2022, 17, e0268767.	1.1	18
3	Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine. Science Translational Medicine, 2022, 14, .	5.8	7
4	Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge model. The Lancet Healthy Longevity, 2022, 3, e405-e416.	2.0	9
5	T cell immunity to SARS-CoV-2 following natural infection and vaccination. Biochemical and Biophysical Research Communications, 2021, 538, 211-217.	1.0	88
6	Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. Immunity, 2021, 54, 769-780.e6.	6.6	37
7	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science, 2021, 373, .	6.0	174
8	Level of maternal respiratory syncytial virus (RSV) F antibodies in hospitalized children and correlates of protection. International Journal of Infectious Diseases, 2021, 109, 56-62.	1.5	7
9	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity, 2021, 54, 1869-1882.e6.	6.6	59
10	Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. Lancet Respiratory Medicine,the, 2021, 9, 1111-1120.	5.2	38
11	Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine. Frontiers in Immunology, 2021, 12, 772864.	2.2	21
12	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 2020, 586, 567-571.	13.7	1,153
13	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. Cell Reports, 2020, 33, 108322.	2.9	59
14	Development of a potent Zika virus vaccine using self-amplifying messenger RNA. Science Advances, 2020, 6, eaba5068.	4.7	50
15	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine, 2020, 383, 1544-1555.	13.9	936
16	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Science Translational Medicine, 2020, 12, .	5.8	30
17	A proof of concept for structure-based vaccine design targeting RSV in humans. Science, 2019, 365, 505-509.	6.0	207
18	Immunological Lessons from Respiratory Syncytial Virus Vaccine Development. Immunity, 2019, 51, 429-442.	6.6	99

#	Article	IF	Citations
19	Epitope-Specific Serological Assays for RSV: Conformation Matters. Vaccines, 2019, 7, 23.	2.1	26